18650512

Source:http://linkedlifedata.com/resource/pubmed/id/18650512

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019704, umls-concept:C0021311, umls-concept:C0087111, umls-concept:C0332325, umls-concept:C1706907, umls-concept:C1871526
pubmed:issue	4
pubmed:dateCreated	2008-7-24
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00293254, http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00293267
pubmed:abstractText	Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18650512-18650518
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0255562
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/HIV Integrase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/MK 0518, http://linkedlifedata.com/resource/pubmed/chemical/Organic Chemicals, http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidinones, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	1533-4406
pubmed:author	pubmed-author:BENCHMRK Study Teams, pubmed-author:ChenJoshuaJ, pubmed-author:ClotetBonaventuraB, pubmed-author:CooperDavid ADA, pubmed-author:DiNubileMark JMJ, pubmed-author:EronJoseph EJE, pubmed-author:GatellJose MJM, pubmed-author:GildeLucinda RLR, pubmed-author:HazudaDaria JDJ, pubmed-author:IsaacsRobin DRD, pubmed-author:KatlamaChristineC, pubmed-author:KillarJohn AJA, pubmed-author:KumarPrincy NPN, pubmed-author:LazzarinAdrianoA, pubmed-author:LennoxJeffrey LJL, pubmed-author:LoutfyMona RMR, pubmed-author:MarkowitzMartinM, pubmed-author:MeibohmAnne RAR, pubmed-author:MillerMichael DMD, pubmed-author:NesslyMichael LML, pubmed-author:NguyenBach-YenBY, pubmed-author:RhodesRand RRR, pubmed-author:RockstrohJurgen KJK, pubmed-author:RyanDesmond MDM, pubmed-author:SchechterMauroM, pubmed-author:SteigbigelRoy TRT, pubmed-author:StrohmaierKim MKM, pubmed-author:TepplerHedyH, pubmed-author:YeniPatrickP, pubmed-author:ZhaoJingJ
pubmed:copyrightInfo	2008 Massachusetts Medical Society
pubmed:issnType	Electronic
pubmed:day	24
pubmed:volume	359
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	339-54
pubmed:dateRevised	2008-11-21
pubmed:meshHeading	pubmed-meshheading:18650512-Adolescent, pubmed-meshheading:18650512-Adult, pubmed-meshheading:18650512-Aged, pubmed-meshheading:18650512-CD4 Lymphocyte Count, pubmed-meshheading:18650512-Double-Blind Method, pubmed-meshheading:18650512-Drug Resistance, Viral, pubmed-meshheading:18650512-Drug Therapy, Combination, pubmed-meshheading:18650512-Female, pubmed-meshheading:18650512-Follow-Up Studies, pubmed-meshheading:18650512-HIV Infections, pubmed-meshheading:18650512-HIV Integrase Inhibitors, pubmed-meshheading:18650512-HIV-1, pubmed-meshheading:18650512-Humans, pubmed-meshheading:18650512-Logistic Models, pubmed-meshheading:18650512-Male, pubmed-meshheading:18650512-Middle Aged, pubmed-meshheading:18650512-Neoplasms, pubmed-meshheading:18650512-Organic Chemicals, pubmed-meshheading:18650512-Pyrrolidinones, pubmed-meshheading:18650512-RNA, Viral, pubmed-meshheading:18650512-Treatment Outcome, pubmed-meshheading:18650512-Viral Load
pubmed:year	2008
pubmed:articleTitle	Raltegravir with optimized background therapy for resistant HIV-1 infection.
pubmed:affiliation	State University of New York at Stony Brook, Stony Brook, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III